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Abstract
Background: A central goal in Huntington’s disease (HD) research is to identify and prioritize candidate targets for
neuroprotective intervention, which requires genome-scale information on the modifiers of early-stage neuron
injury in HD.
Results: Here, we performed a large-scale RNA interference screen in C. elegans strains that express N-terminal
huntingtin (htt) in touch receptor neurons. These neurons control the response to light touch. Their function is
strongly impaired by expanded polyglutamines (128Q) as shown by the nearly complete loss of touch response in
adult animals, providing an in vivo model in which to manipulate the early phases of expanded-polyQ
neurotoxicity. In total, 6034 genes were examined, revealing 662 gene inactivations that either reduce or aggravate
defective touch response in 128Q animals. Several genes were previously implicated in HD or neurodegenerative
disease, suggesting that this screen has effectively identified candidate targets for HD. Network-based analysis
emphasized a subset of high-confidence modifier genes in pathways of interest in HD including metabolic,
neurodevelopmental and pro-survival pathways. Finally, 49 modifiers of 128Q-neuron dysfunction that are
dysregulated in the striatum of either R/2 or CHL2 HD mice, or both, were identified.
Conclusions: Collectively, these results highlight the relevance to HD pathogenesis, providing novel information
on the potential therapeutic targets for neuroprotection in HD.
Background
Huntington’s disease (HD) is a dominantly-inherited dis-
order caused by expanded polyglutamine (polyQ) tracts
in the N-terminal portion of huntingtin (htt) and char-
acterized by striatal and cortical degeneration [1]. While
HD pathogenesis might involve a gain of toxic proper-
ties by mutant htt as well as a loss of normal htt func-
tion, several studies have emphasized a critical role of
misfolded N-terminal fragments of mutant htt [2,3] that
are natural products of htt processing [4]. Huntingtin is
thought to have a large number of partner proteins
involved in a variety of biological processes [5-8], sug-
gesting that polyglutamine expansion in htt may alter
several biological processes that are essential to cellular
homeostasis and neuron survival. Consistent with this
possibility, transcriptomic analyses have revealed that
mutant/polyQ-expanded htt expression may change the
expression of a large number of genes in the caudate
nucleus of HD subjects [9] and in the brain of fragment,
knock-in and full-length mouse models of HD [10].
Given the complexity of alterations in cells and tissues
expressing expanded polyQ/htt, gene perturbation
screens are expected to shed light on the mechanisms
that may be critical for cell response to mutant polyQ
expression. Additionally, the integration of gene pertur-
bation data with other types of ‘omics data such as for
example gene expression profiles in HD mice [10] might
fulfill the need for target profiling and prioritisation in
HD. This may be particularly important when compar-
ing target gene activity for the regulation of neuronal
dysfunction versus that of neuronal death. Before the
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indeed thought to be an early-stage component of the
pathogenic process in HD [3,11]. However, neuronal cell
dysfunction is not easily tractable in vivo. Interestingly,
the genetic regulation of response to light touch by
mechanosensory neurons in C. elegans has been the
subject of detailed analysis [12]. By targeting polyQ
expression to C. elegans touch cells, we previously gen-
erated a model that recapitulates an early phase of
expanded polyQ neurotoxicity, namely neuronal dys-
function in the absence of cell death [13,14]. In these
animals, exon 1 like htt fused to CFP was expressed in
touch receptor neurons under the control of the promo-
ter for the mec-3 gene (mec-3p) [14]. This promoter is
active from the early stages of embryonic development
through adulthood [15]. Young adults expressing normal
polyQs (19Q) have a moderate loss of touch response
with no or little change in touch cell morphology,
whereas young adults expressing expanded polyQs
(128Q) show a dramatic loss of touch response, a beha-
vioral phenotype that is accompanied by a strong level
of axonal dystrophy [14]. Axonal dystrophy is followed
by late-onset axonal degeneration as observed in older
adult animals (unpublished data). The loss of touch
response in expanded-polyQ nematodes can be manipu-
lated by genetic means, as exemplified by the protective
effect of sirtuin overexpression and aggravating effect of
loss-of-function in the sir-2.1/SIRT1–daf-16/FOXO cell
survival pathway [14]. These animals thus provide an in
vivo model in which to screen for modifiers of neuron
dysfunction induced by expanded polyQs. Here, we used
128Q nematodes in a large-scale functional RNA inter-
ference (RNAi) screen for modulation of response to
touch. Additionally, we used 19Q nematodes to test a
subset of the 128Q-confirmed hits for modulation of
response to touch in 19Q nematodes. To this end, we
generated polyQ strains with enhanced response of
touch receptor neurons to double-standed RNA deliv-
ered by feeding. We then undertook a semi-directed
screening approach to test a total of 6034 genes includ-
ing 5128 genes tested at random and 906 genes that
belong to major signaling pathways (16-19). This led us
to identify 662 genes that either reduce or aggravate the
loss of response to light touch when knocked-down by
RNAi in 128Q nematodes. Screening in 19Q nematodes
suggested that greater than 90% of these genes specifi-
cally modify 128Q cytotoxicity. In-depth data analysis
emphasized a role for cell differentiation/survival, meta-
bolic and neurodegenerative disease pathways in the
modulation of expanded-polyQ cytotoxicity. Addition-
ally, data analysis and comparisons to gene expression
data from HD mice emphasized the potential value of
this RNAi dataset for target discovery in HD.
Methods
C. elegans strains
Nematode strains were handled using standard methods
[16]. Integrated polyQ strains used in this study were
previously described [17,18]. Briefly, ID245 (igIs245[mec-
3p::htt57-19Q::CFP; lin-15(+); mec-7p::YFP]) and ID1
(igIs1[mec-3p::htt57-128Q::CFP; lin-15(+); mec-7p::YFP])
stably co-express the first 57 amino acids of human
huntingtin (htt) fused to CFP under the control of the
promoter of the mec-3 gene and YFP under the control
of the promoter of the mec-7 gene. We previously
reported that ID245 animals show a moderate loss of
response to light touch at the tail whereas ID1 animals
show a strong loss of response to light touch at the tail,
the latter phenotype accompanied by axonal swelling
[14]. The enhanced RNAi strain YY13 which carries the
rrf-3(mg373) mutation [19] was provided by the Caenor-
habditis Genetics Center, which is funded by the NIH
National Center for Research Resources (NCRR). To
construct polyQ strains with enhanced RNAi sensitivity
in neurons, we crossed YY13 animals with either ID245
or ID1 animals to generate strain ID448 (igIs245[mec-
3p::htt57-19Q::CFP;lin-15(+);mec-7p::YFP];rrf-3(pk1426))
and strain ID447 (igIs1[mec-3p::htt57-128Q::CFP;lin-15
(+);mec-7p::YFP];rrf-3(pk1426)), respectively. The ID448
and ID447 strains were tested for sensitivity of touch
receptor neurons to RNAi and subsequently used to
screen the C. elegans ORF-RNAi library (Open Biosys-
tems, AL) that includes clones from the C. elegans
ORFeome library v1.1 [20] as detailed below.
RNAi screen
Bacterial clones from the C. elegans ORF-RNAi library
were grown in 500 μl of LB culture medium supplemen-
ted with ampicillin (100 μg/ml) and tetracyclin (12.5 μg/
ml), and they were induced by adding 10 μlo fI P T G
(12.5 mg/ml) 4 hours prior to incubation with nema-
todes. Synchronized L1 larvae were obtained by hypo-
chlorite extraction using standard methods [16] and
t h e yw e r eg r o w na t2 0 ° Co nP e t r id i s h e su n t i lt h e y
reach the young adult stage. The day of incubation in
96-well plates (D0), two young adult animals were incu-
bated per well. Each of the wells contained 33.6 μlo f
bacterial culture and 16.6 μl of M9 media supplemented
with cholesterol, ampicillin, tetracyclin, fungizone and
IPTG. Incubation was performed at 20°C during 4 days
until the animals reached adulthood and produce late
L4 larvae. To ensure appropriate feeding of the nema-
todes in the well, 16.6 μl of bacterial cultures expressing
RNAi clones were added at day 1. At day 4, animals
were transferred to agar plates and allowed to recover
for 15 minutes. RNAi clones producing lethality, larval
arrest, egg-laying defect, developmental delay or any
Lejeune et al. BMC Genomics 2012, 13:91
http://www.biomedcentral.com/1471-2164/13/91
Page 2 of 14other abnormalities such as morphological abnormalities
(2243 RNAi clones) were excluded from further analysis.
For RNAi clones that did not alter nematode growth
and morphology, the two P0 animals (old and dark
nematodes) initially incubated in the well were manually
removed from the plate and young adults (F1 progeny)
were assayed for light touch response as previously
described [13]. Briefly, touch tests involved scoring for
the response to light touch at the tail by using a fine
hair. Touch test were performed by scoring 5 touches at
the tail of the animal for 70-90 animals/RNAi clone/test.
Ordinarily, wild-type animals will respond by backing
away from the touch. The responses were recorded for
every animal such that, for example, 4 responses out of
5 at the tail is given as 80% responsiveness, and the
mean values for responsiveness were retained for further
analysis of the data. A score for change in touch
response (S) was calculated as [(Percent response -
mean baseline)/mean baseline]. Using this formula, the
maximally-achievable score is 4.55 (maximal suppression
of 128Q cytotoxicity, i.e. 100% responsiveness) and the
minimally-achievable score is -1 (maximal aggravation
of 128Q cytotoxicity). The baseline in the assay was
monitored across the entire time of the screening from
the incubation of the animals treated with the empty
vector L4440 in all of the 96-well plates assayed. The
cumulated baseline over the entire time of the screening
w a so b s e r v e dt ob es t a b l e( 2 0 . 6±3 % )a n dt h ec u m u -
lated baseline/month was used to calculate S scores. Sta-
tistical analysis was performed using one-way ANOVA
and the Tukey’s Multiple Comparison Test. To decrease
the risk for false positives, RNAi clones were scored as
positive hits (suppressors or enhancers) if the S ± SD
value was outside the baseline ± (SD*2.6). Initial hits
(suppressors, enhancers) were tested for confirmation or
invalidation of effect on touch response and the result-
ing data were retained for biological content analysis.
All of the screening assays were performed by investiga-
tors that were trained to score touch response of 128Q
animals in a similar way using blind assays.
Prior to performing the RNAi screen, the efficiency of
gene inactivation in touch receptor neurons was tested
by incubating ID447 L1 larvae in 96-well plates (1 lar-
vae/well) with bacteria expressing either RNAi against
GFP (plasmid pL4417) or empty vector (plasmid
pL4440). Incubation was performed as described above
until F1 young adults are produced. At the end of incu-
bation, 70-90 animals/genotype were moved to agar
plates and mounted on slides, and YFP levels in touch
cells (mec-7p target cells) were measured at high (63X)
magnification using a fluorescence microscope (Zeiss
Axioplan Imaging II) and image analysis software
(Image J). Additionally, YFP mRNA levels were mea-
sured by qRT-PCR from whole animals using standard
methods. All of the nematode experiments were per-
formed at least three times. Student’st - t e s t sw e r eu s e d
for statistical analysis of YFP mRNA levels and YFP
expression levels.
Data analysis
The final screening results were initially classified using
Gene Ontology (GO) annotations for Biological Process,
Molecular Function and Cellular Component http://
www.geneontology.org/[21]. GO enrichment tests were
performed using Ontologizer v 2.0 [22]. Additionally, we
used hypergeometric tests tot e s tf o rg e n es e te n r i c h -
ment [23,24]. The gene sets used for enrichment analy-
sis were established using core components of (i)
canonical pathways based on Wormbook http://www.
wormbook.org, KEGG http://www.genome.ad.jp/kegg/
[25] and Panther http://www.pantherdb.org/pathway/.
To analyze further the biological content of RNAi
clones confirmed to modulate 128Q toxicity, we per-
formed network-boosted data analysis. To this end, we
subjected the RNAi data to spectral decomposition ana-
lysis using the integrated C. elegans network Wormnet
v.2 [26]. This large-coverage network contains gene
interaction data that were established according to sev-
eral types of evidences derived from multiple organisms,
including several types of gene interactions based on
gene co-expression (microarray measurements of the
expression of C. elegans mRNAs), protein-protein inter-
actions including genome-wide yeast two-hybrid interac-
tions between C. elegans proteins and protein-protein
interactions from the Worm Interactome database [27],
genetic interactions from WormBase [28], human and
fly ‘interologs’ i.e. human and fly protein interactions
[29,30], Yeast ‘associalogs’ i.e. functional interactions
transferred from the yeast functional gene network [31],
phylogenic profiles (comparative genomics linkages
derived from the analysis of bacterial and archaeal gen-
omes), gene neighbors and co-citation (literature-mined
C. elegans gene associations). To increase the power of
spectral decomposition analysis in detecting pathways,
we also used a more homogenous network containing
high confidence interactions, namely Core Wormnet
[26] in which we omitted co-expression and co-citation
links. To perform spectral decomposition analysis, we
developed an enhanced version of the previously
described [32] Fourier-like analysis. This approach is
based on the spectral decomposition of gene activity
profiles with respect to the connectivity of the reference
network. S scores in the RNAi screen are considered as
a ‘signal’ and the Fourier transformation decomposes
the signal as a superposition of signals at different fre-
quencies, with 40 successive attenuations performed
[32]. The aim of these transformations is to keep the
low-frequency signals and discard the high frequency
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nectivity. The logic behind this procedure is that highly
inter-connected genes may be implicated in the same
pathway and may fluctuate in the same direction [32].
Starting from the raw RNAi screen data, we iteratively
removed the high-frequency components 2.5% at a time,
resulting in 40 increasingly smoothed versions of the
data. Given a smoothed gene activity data, we consid-
ered modules as groups of connected genes with a signal
> mean S-score + SD or < mean S-score-SD. Addition-
ally, and to generate an even more relevant signal and
robust information, we selected the modules that were
present after the 4
th attenuation and that showed a
stable gene content (≥ 40% of the genes with a value
over the threshold) for at least 2 successive attenuations.
The resulting modules were filtered for redundant gene
content and functional content of the remaining mod-
ules analyzed using Ontologizer v 2.0 [22]. Additionally,
we used hypergeometric tests to annotate for signaling
pathways (gene lists extracted from Wormbook, KEGG
and Panther), druggable genes [33], htt partners [7,34]
and genes involved in autophagy, mitochondrial function
and synaptic activity (gene lists kindly provided by the
CHDI Foundation). Information on conservation in
humans was derived from Inparanoid clusters [35]. In
addition to tables included herein, the results of net-
work-boosted data analysis are displayed in a freely-
accessible database (see http://www.broca.inserm.fr/
EHDN2/RNAiscreen) for the vizualisation of modules.
This database allows the users to browse the results
using GO/KEGG/Panther annotations and other annota-
tions of interest, and it uses VisANT 3.5 for graph
visualization [36]. We used confidence graphs for dis-
play of modules by normalizing the statistical weights
for functional interactions as available in Wormnet v 2.0
[26].
Results
The touch receptor neurons of F1 128Q;rrf-3 animals are
sensitive to RNAi
To construct polyQ strains with enhanced RNAi sensi-
tivity in neurons, we crossed the enhanced RNAi strain
YY13 which carries the rrf-3(mg373)II mutation [19]
with integrated strains that co-express N-terminal
(amino acids 1-57) htt under the control of mec3-p and
YFP under the control of mec7-p [14]. This resulted in
strain ID448 (19Q;rrf-3) and strain ID447(128Q;rrf-3).
The efficiency of gene inactivation in touch receptor
neurons was tested by incubating strain ID447 L1 larvae
in 96-well plates with bacteria expressing either RNAi
against GFP (plasmid L4417) or empty vector (plasmid
L4440) until F1 young adults are produced. Treatment
with RNAi against GFP induced an overall reduction of
YFP expression levels in mec7-p target cells as illustrated
in Figure 1A/B. The level of YFP mRNA expression was
strongly reduced (about 80%) by RNAi against GFP
compared to empty vector (Figure 1C). Additionally, the
level of YFP expression in the mechanosensory neurons
that control the response to touch at the tail (PLM neu-
rons) was reduced by RNAi against GFP compared to
empty vector (Figure 1D). Collectively, these results
indicated that the touch receptor neurons of F1 young
adults are sensitive to RNAi. Consistent with previous
reports [37], no or little reduction of YFP levels was
detected in F0 young adults (data not shown).
A large-scale functional RNAi screen identifies 662 genes
that modulate neuron dysfunction in expanded-
polyglutamine nematodes
U s i n g1 2 8 Qn e m a t o d e si nt h errf-3 sensitized back-
ground, we then conducted a primary RNAi screen for
the modulation of neuronal dysfunction. This screen
was based on the manual quantification of response to
light touch at the tail of F1 young adult animals. We
screened 6260 RNAi clones equaling 6034 genes in the
C. elegans genome (Figure 2). To decrease the risk for
false positive, we applied a stringent threshold where
the modification of touch response was considered sig-
nificant if the score for touch response was outside the
mean baseline ± SD*2.6 (Additional file 1: Figure S1).
This screen identified 2243 RNAi clones (2211 genes)
that caused toxicity phenotypes such as lethality, larval
arrest, egg-laying defect, developmental delay and other
abnormalities such as morphological abnormalities, 3101
RNAi clones (3054 genes) that showed no effect and
916 RNAi clones (769 genes) that modulated neuronal
dysfunction (Figure 2, Additional file 2: Table S1; Addi-
tional file 3: Table S2). The latter class of RNAi clones
was subjected to a second screen in 128Q nematodes,
which led to the identification of 664 RNAi clones con-
firmed to modulate neuronal dysfunction. These clones
corresponded to 662 genes, consisting of 399 genes that
reduced neuronal dysfunction when knocked-down by
RNAi and 263 genes that enhanced neuronal dysfunc-
tion when knocked-down by RNAi (Additional file 4:
Table S3). As previously reported, 128Q nematodes
show at least 80% decreased touch response at the tail
with a strong level of axonal dystrophy, whereas 19Q
nematodes show a 45-50% reduction of touch response
at the tail without significant axonal dystrophy [14].
Since our screen was based on the manual quantifica-
tion of touch response in 70-90 animals/RNAi clone,
which is considerably more labour-intensive and time-
consuming compared to faster RNAi screens such as
those looking for modifiers of mutant htt aggregation
[38,39], we evaluated whether the modifiers of 128Q-
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function in 19Q;rrf-3 nematodes by testing a subset of
the 662 genes (245 genes choosen at random). Only 15/
245 genes (6.1%) were found to modulate neuronal dys-
function in 19Q;rrf-3 nematodes when knocked-down
by RNAi (Additional file 5: Table S4), suggesting that
most of the 662 genes emphasized by screens in 128Q;
rrf-3 nematodes specifically modify 128Q cytotoxicity.
Genome-wide RNAi screens previously aimed at identi-
fying modifiers of polyQ aggregation in C. elegans
[40,41], Consistent with the notion that aggregation and
cytotoxicity can be genetically uncoupled [41], the over-
lap with our RNAi screen was small with 12 modifiers
of 128Q-neuron dysfunction previously found to
enhance the aggregation of 35Q-peptides when
knocked-down by RNAi [40] and three other modifiers
of 128Q-neuron dysfunction previously found to sup-
press the aggregation of 35Q-peptides when knocked-
down by RNAi [41] (Additional file 6: Table S5).
In-depth data analysis emphasizes modifiers of 128Q-
neuron dysfunction in pathways associated with
metabolism, development, survival and
neurodegenerative disease
The 662 genes associated with the modification of
128Q-neuron dysfunction appeared to encompass a vari-
ety of biological processes (cell death, protein folding,
intracellular transport, metabolic processes, response to
stress, stress-activated pathways) that may have a role in
neurodegenerative disease pathogenesis as suggested by
their functional classification using GO annotations (Fig-
ure 3, Additional file 7: Tables S6; Additional file 8:
Table S7). To further assess the biological content cor-
responding to modifiers of 128Q-neuron dysfunction,
we performed two types of analysis. First, we used gene
lists describing major signaling pathways (see Materials
and Methods) to perform gene set enrichment analyses.
This analysis was performed for genes that either aggra-
vate (herein referred to as ‘protection-associated’ or PA
Figure 1 Reduction of YFP expression in 128Q;rff-3 nematodes treated with RNAi against GFP. Following incubation of ID447 L1 larvae
with bacteria expressing either empty vector (pL4440) or RNAi against GFP (pL4417) until F1 young adults are produced, YFP levels in PLM
touch receptor cells were measured by image analysis, and YFP mRNA levels were measured by qRT-PCR from whole animals. (A) Representative
image showing YFP expression (pseudocolored in green) in animals treated with empty vector. The name of the mec-7p target cells is indicated.
The insert shows a closer view of the left (PLMl) and right (PLMr) PLM cell. (B) Representative image showing reduced YFP expression in animals
treated with RNAi against GFP. The yellow arrow indicates natural auto-fluorescence of the gut granules. This fluorescence is also present in the
control animals and works as an internal control of light intensity, showing that pictures were collected in the confocal microscope under the
same conditions. The insert shows a closer view of PLM cell left (PLMl) and right (PLMr). (C) YFP mRNA levels are reduced by treatment with
pL4417. Data are means ± SE (n = 5). ***P < 0.001 compared to pL4440. (D) YFP expression levels in PLM cells are reduced by treatment with
pL4417. Data are means ± SEM (n = 3) as compiled from greater than 70 animals/experiment. ***P < 0.001 compared to pL4440. Scale bar is 100
μm in all panels.
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process-associated’ or PPA genes) 128Q-neuron dys-
function when knocked-down by RNAi. Pathway analy-
sis for PA genes identified eight metabolic pathways
such as for example those involved in glycolysis and
amino acid metabolism (Table 1). Consistent with the
notion that mutant htt expression may dysregulate a
large number of genes and alter a variety of biological
processes [3,10], pathway analysis for PPA genes identi-
fied three main pathway categories, including pathways
primarily involved in metabolism (glycolysis, amino acid
metabolism), cytokine signaling/immune system (inter-
feron-gamma signaling, interleukin signaling, Toll recep-
tor signaling) and cellular differentiation and
homeostasis (IGF pathway, angiogenesis, integrin signal-
ing, p53 pathway by glucose deprivation, FGF signaling,
EGF signaling, Toll receptor signaling) (Table 2). Inter-
estingly, the latter category included the Alzheimer’s dis-
ease (AD)-amyloid secretase pathway, pathways
previously associated to neu r o p r o t e c t i o ni nH Ds u c ha s
IGF signaling [14] and FGF signaling [42], pathways that
could play a role in neurodegenerative disease pathogen-
esis such as EGF signaling [43], and pathways having a
dual role in neurodegeneration and neuroprotection
such as Toll receptor signaling [44]. These observations
illustrated the revelance of our RNAi dataset to neuro-
degeneration. Given that PPA genes might constitute
preferred targets for therapeutic intervention, these
results suggested that several of the targets for early-
stage neuroprotection in HD may lie in the pathways
that are important to neuronal cell differentiation and
survival.
In contrast to metabolic pathways which may show a
rather simple structure, pathways that respond to exter-
nal stimuli to regulate gene expression may be highly
inter-connected, and they may have highly-branched
structures and several biological outcomes. Additionally,
RNAi-based screens may generate noise due to off-tar-
get effects and variations in the degree of knockdown of
target genes. Therefore, to map RNAi activity to func-
tional clusters and to identify a more reliable set of
genes from the RNAi hits, we used a network-based
approach. To this end, we used a Fourier-like analysis
[32] based on the reference network Wormnet [26]. To
enhance the discriminative power and reliability of this
analysis, we developed and applied an optimized version
of the Fourier-like analysis (see Materials and Methods).
We analyzed the gene set for which a score for activity
Figure 2 Overview of the screening and data analysis strategy.
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Page 6 of 14Figure 3 Gene Ontology classification of genes that modulate neuronal dysfunction induced by expanded polyQ expression.G e n e s
were classified based on their functional annotations in the GO categories ‘Biological Process’, ‘Molecular Function’ and ‘Cellular component’. Pie-
charts for the most frequent ‘Biological process’ categories (corresponding to at least 18 genes) are shown for gene inactivations that reduced
128Q-neuron dysfunction (A) and those that aggravated neuronal dysfunction (B). The number of genes is indicated. See the indicated
supplementary tables (Supplementary Tables 4-5) for the complete lists of genes in each GO category.
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Pathway P value Gene
Ascorbate and aldarate
metabolism
0.00000 B0218.8/clec-52, C01G6.1/aqp-2, C08B11.8, C12C8.2, C13B9.1, C36E8.3/pxd-1, C50D2.8, C52B9.1/cka-2,
C52E4.1/cpr-1, C53B7.3, C54C8.9/nlp-39, D1025.4/nspc-20, D1086.3, F08B1.1/vhp-1, F29G6.2, F38E11.1/hsp-
12.3, F45C12.7/btb-6, F46H5.3, F49E12.1, F54B11.3/unc-84, F54F7.3, F56D6.2/clec-67, K07E3.3/dao-3,
K08D8.3, K09C4.5, M02F4.7/clec-265, M03F4.7/calu-1, T07H3.3/math-38, T16H12.1, T23B3.2, T23H2.2/snt-4,
W08D2.4/fat-3, Y38H6C.3/dct-14, ZC410.5, ZC416.6, ZK6.11
Starch and sucrose metabolism 0.00119 F57B10.7/tre-1, R05F9.6, T22F3.3, Y87G2A.8/gpi-1
Tyrosine metabolism 0.00535 B0334.11/ooc-3, F46C3.1/pek-1, M110.5/dab-1
Amino sugar and nucleotide
sugar metabolism
0.01885 F22B3.4, R05F9.6, Y87G2A.8/gpi-1
Glycolysis 0.03209 T03F1.3/pgk-1, Y87G2A.8/gpi-1
Glycolysis/Gluconeogenesis 0.03332 R05F9.6, T03F1.3/pgk-1, Y87G2A.8/gpi-1
Fatty acid biosynthesis 0.03415 W09B6.1/pod-2
Pentose phosphate pathway 0.04375 R05F9.6, Y87G2A.8/gpi-1
Pathway analysis was based on hypergeomeric tests using pathways from Wormbook, KEGG and Panther. P < 0.05 was considered significant and results are
shown by increasing P values.
Table 2 Pathway analysis for 399 genes that reduced 128Q-neuron dysfunction when knocked-down by RNAi
Pathway P value Gene
Ascorbate and aldarate metabolism 0.00000 B0281.5, B0286.3, B0478.1/jnk-1, C06B3.4/stdh-1, C08E3.4/fbxa-161, C08F8.5/fbxb-9, C09G1.1/pqn-11,
C10C5.4, C10C5.5, C10G11.5/pnk-1, C17G10.5/lys-8, C17H12.8, C39D10.7, C45B11.3/dhs-18, C46E10.7/
srh-99, C54D10.3, D1054.10, D2045.6/cul-1, F07F6.1, F07F6.5/dct-5, F09B12.3, F17E5.1/lin-2, F28D1.5/
thn-2, F29G9.1, F31C3.6, F36F2.1, F38E11.2/hsp-12.6, F38H4.8/ech-2, F41B5.4/cyp-33C3, F42G10.1,
F43G9.5, F44D12.8, F47C10.2/btb-21, F52H3.5, F53C3.5, F56D5.5, F56G4.3/pes-2.2, F57C9.4, F57H12.7/
mec-17, H04M03.1, H10D18.2/scl-12, K02B12.2, K02E11.5, K10B3.8/gpd-2, M01E11.2, M02D8.4, R03E9.1/
mdl-1, R05F9.10/sgt-1, R12B2.5/mdt-15, R12H7.2/asp-4, T03F6.1/qdpr-1, T17H7.1, T20B5.3/oga-1,
T21C9.8/ttr-23, T22G5.2/lbp-7, T24B8.5, W02D3.1, W03D2.6, W05H9.1, Y106G6H.7/sec-8, Y106G6H.9,
Y38H6C.1/dct-16, Y43C5B.2, Y47D3B.7/sbp-1, ZK1127.10, ZK1290.6/rnh-1.1, ZK384.2/scl-20, ZK520.4/
cul-2, ZK550.6, ZK637.8/unc-32, ZK829.6/tgt-1
Sulfate assimilation 0.00001 B0218.3/pmk-1, B0412.2/daf-7, B0478.1/jnk-1, C47G2.2/unc-130, C53D6.2/unc-129, F38A6.1/pha-4,
F43C1.2/mpk-1, T23H2.5/rab-10, Y11D7A.4/rab-28
Pyrimidine metabolism 0.00113 B0304.1/hlh-1, B0478.1/jnk-1, B0547.1/csn-5, C04E7.2/sor-3, C07B5.5/nuc-1, C25D7.3/sdc-3, C34E10.7/
cnd-1, C37A2.4/cye-1, C47G2.2/unc-130, F14F3.1/vab-3, F38A6.1/pha-4, F56A8.7/unc-64, K01G5.2/hpl-
2, Y47D3A.6/tra-1, ZK520.4/cul-2
Pyridoxal phosphate salvage
pathway
0.00176 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1, Y18D10A.5/gsk-3, Y38F1A.10/max-2
Oxytocin receptor mediated
signaling
0.00236 B0478.1/jnk-1, B0547.1/csn-5, C44H4.6, F43C1.2/mpk-1, Y11D7A.4/rab-28, Y18D10A.5/gsk-3
Interferon-gamma signaling 0.00251 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1
Glycosphingolipid biosynthesis -
ganglio series
0.00297 T14F9.3/hex-1, T26C5.3
Cyanoamino acid metabolism 0.00340 B0035.8/his-48, B0304.1/hlh-1, B0478.1/jnk-1, B0547.1/csn-5, C02B8.4/hlh-8, C04E7.2/sor-3, C07B5.5/
nuc-1, C09G9.7, C18A3.1, C25A1.11/aha-1, C25D7.3/sdc-3, C29F9.5, C34E10.7/cnd-1, C37A2.4/cye-1,
C47G2.2/unc-130, F11A10.1/lex-1, F14F3.1/vab-3, F22D3.1/ceh-38, F22F1.1/hil-3, F38A6.1/pha-4,
F45F2.4/his-7, F54C8.2/cpar-1, F56A8.7/unc-64, K01G5.2/hpl-2, K02B9.4/elt-3, R03E9.1/mdl-1, R05F9.10/
sgt-1, R07B1.1/vab-15, R13H8.1/daf-16, T05A6.1/cki-1, T19B10.11/mxl-1, T27F2.1/skp-1, W06E11.1,
Y39B6A.2/pph-5, Y47D3A.6/tra-1, Y47D3B.7/sbp-1, Y49E10.1/rpt-6, Y57E12AL.5/mdt-6, ZC204.2,
ZK131.7/his-13, ZK520.4/cul-2, ZK652.5/ceh-23
Taurine/hypotaurine metabolism 0.00348 F56A8.7/unc-64, K02D10.5, T10H9.3, Y22F5A.3/ric-4
Glycolysis/Gluconeogenesis 0.00365 AC3.7/ugt-1, C05C8.3/fkb-3, C06B3.4/stdh-1, C07B5.5/nuc-1, F11A5.12/stdh-2, F38E11.2/hsp-12.6,
K10B3.8/gpd-2, R03E9.1/mdl-1, R12B2.5/mdt-15, R13H8.1/daf-16, T22G5.2/lbp-7, T28B8.2/ins-18
Selenocompound metabolism 0.00365 AC3.7/ugt-1, C05C8.3/fkb-3, C06B3.4/stdh-1, C07B5.5/nuc-1, F11A5.12/stdh-2, F38E11.2/hsp-12.6,
K10B3.8/gpd-2, R03E9.1/mdl-1, R12B2.5/mdt-15, R13H8.1/daf-16, T22G5.2/lbp-7, T28B8.2/ins-18
Insulin_IGF pathway-protein kinase B
signaling cascade
0.00404 C44H4.6, C47G2.2/unc-130, F38A6.1/pha-4, Y18D10A.5/gsk-3
Salvage pyrimidine ribonucleotides 0.00417 F42G9.7/snt-2, K02D10.5, Y22F5A.3/ric-4
Tetrahydrofolate biosynthesis 0.00417 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1
Apoptosis signaling 0.00503 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1, Y18D10A.5/gsk-3, Y38F1A.10/max-2
Glycosaminoglycan degradation 0.00520 K09E4.4, T14F9.3/hex-1
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Page 8 of 14(S score) was available (genes that either modulate
128Q-neuron dysfunction or produce no effect when
knocked-down by RNAi). The modules resulting from
this analysis were annotated by using Gene Ontology,
KEGG and Panther pathways and gene lists of interest
(conserved genes, druggable genes, htt partners, genes
involved in autophagy, mitochondrial function and
synaptic activity). These analyses identified a more reli-
able set of 286 modifier genes as distributed in 137
modules for suppression of 128Q-neuron dysfunction by
RNAi and 105 modules for aggravation of 128Q-neuron
dysfunction by RNAi (Additional file 9: Table S8;
Additional file 10: Table S9). Modules of variable sizes
were obtained (2-50 genes) for either suppression or
aggravation of 128Q-neuron dysfunction. Of note, small
modules are equally significant compared to large mod-
ules as the size of the resulting modules was always dri-
ven by the stable and best balance between gene
connectivity and gene activity during the spectral
decomposition process (see Materials and Methods).
The modules and their content can be visualized using a
freely-accessible database (see http://www.broca.inserm.
fr/EHDN2/RNAiscreen) that contains a query page and
interactive graphical interface [36]. Our network-based
Table 2 Pathway analysis for 399 genes that reduced 128Q-neuron dysfunction when knocked-down by RNAi
(Continued)
Angiogenesis 0.00520 C06B3.4/stdh-1, F11A5.12/stdh-2, K04A8.5
mRNA splicing 0.00534 F56A8.7/unc-64, K02D10.5, Y22F5A.3/ric-4, Y48B6A.8/ace-3
Muscarinic acetylcholine receptor 1
and 3 signaling
0.00608 F56A8.7/unc-64, K02D10.5, Y22F5A.3/ric-4, Y48B6A.8/ace-3
Alanine biosynthesis 0.00769 K02D10.5, K08F8.4/pah-1, Y22F5A.3/ric-4
Butanoate metabolism 0.00777 C06B3.4/stdh-1, F11A5.12/stdh-2, K03A1.5/sur-5, T02G5.7
5-Hydroxytryptamine biosynthesis 0.00798 K02D10.5, Y22F5A.3/ric-4
Interleukin signaling 0.00974 C47G2.2/unc-130, F38A6.1/pha-4, F43C1.2/mpk-1, Y18D10A.5/gsk-3
Amino sugar and nucleotide sugar
metabolism
0.01084 C01F1.3, C53B4.7/bre-1, K08E3.5, T14F9.3/hex-1
Metabotropic glutamate receptor
group II pathway
0.01254 F56A8.7/unc-64, K02D10.5, Y22F5A.3/ric-4
Linoleic acid metabolism 0.01511 C06B3.4/stdh-1, F11A5.12/stdh-2
Beta3 adrenergic receptor signaling 0.01511 K02D10.5, Y22F5A.3/ric-4
Integrin signaling 0.01742 B0218.3/pmk-1, B0478.1/jnk-1, C27B7.8/rap-1, C36B1.1/cle-1, F43C1.2/mpk-1
p53 pathway by glucose deprivation 0.01908 C47G2.2/unc-130, F38A6.1/pha-4, F48E8.1/lon-1, Y18D10A.5/gsk-3
5-Hydroxytryptamine degredation 0.01939 K02D10.5, Y22F5A.3/ric-4
Ornithine degradation 0.02121 B0218.3/pmk-1, B0478.1/jnk-1, T19B10.11/mxl-1
Cortocotropin releasing factor
receptor signaling
0.02412 K02D10.5, Y22F5A.3/ric-4
FGF signaling 0.02627 B0218.3/pmk-1, B0478.1/jnk-1, F26E4.1/sur-6, F43C1.2/mpk-1
N-acetylglucosamine metabolism 0.02712 F56A8.7/unc-64, K02D10.5, T02C12.1/hum-5, Y22F5A.3/ric-4, Y48B6A.8/ace-3
5HT3 type receptor mediated
signaling
0.02928 K02D10.5, Y22F5A.3/ric-4
B cell activation 0.02939 B0218.3/pmk-1, B0478.1/jnk-1, F43C1.2/mpk-1
Fructose and mannose metabolism 0.03565 C06B3.4/stdh-1, C53B4.7/bre-1, F11A5.12/stdh-2
Pantothenate and CoA biosynthesis 0.04074 F25H9.6, T04G9.4
Alzheimer disease-amyloid secretase
pathway
0.04074 K02D10.5, Y22F5A.3/ric-4
Beta1 adrenergic receptor signaling 0.04074 K02D10.5, Y22F5A.3/ric-4
Beta2 adrenergic receptor signaling 0.04074 K02D10.5, Y22F5A.3/ric-4
EGF receptor signaling 0.04229 B0218.3/pmk-1, B0478.1/jnk-1, C27B7.8/rap-1, F43C1.2/mpk-1
Toll receptor signaling 0.04494 C08B6.9/aos-1, F11A10.1/lex-1, F40G9.3/ubc-20, Y49E10.1/rpt-6
Alanine, aspartate and glutamate
metabolism
0.04494 C04E7.2/sor-3, C34E10.7/cnd-1, C47G2.2/unc-130, F57H12.7/mec-17
Serine glycine biosynthesis 0.04620 B0478.1/jnk-1, F43C1.2/mpk-1, Y38F1A.10/max-2
Lysine biosynthesis 0.04869 C25A11.4/ajm-1, C36B1.1/cle-1, F17E5.1/lin-2, F22B5.1/evl-20, F43C9.4/mig-13, F56A8.7/unc-64,
Y22F5A.3/ric-4
Pathway analysis was based on hypergeomeric tests using pathways from Wormbook, KEGG and Panther. P < 0.05 was considered significant and results are
shown by increasing P values.
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Page 9 of 14approach confirmed the trends observed in gene set
enrichment analysis, namely the detection of pathways
involved in metabolism, immune response and develop-
ment. Additionally, it provided insights into the possible
mechanisms of how RNAi hits potentially interact to
modify 128Q-neuron dysfunction. We notably detected
modules seeded by RNAi hits that were annotated for
‘Huntington’s disease’, ‘Parkinson’s disease’ and ‘pantho-
tenate kinase activity’, the latter previously associated
with neurodegeneration [45]. More largely, we detected
modules annotated for biological processes established
or strongly suspected (see [3] for review of HD mechan-
isms) to have a role in neurodegenerative disease patho-
genesis such as ‘oxidative phosphorylation’, ‘cholesterol
biosynthesis’ and ‘cell cycle’. Interestingly, several mod-
ules were annotated for cell differentiation and survival
pathways such as ‘Wnt signaling’, a pathway suspected
t oh a v ear o l ei nH Dp a t h o g e n e s i s[ 4 6 ] ,‘apoptosis sig-
naling’ and ‘integrin signaling’, suggesting that such
pathways might be targeted for therapeutic intervention
in HD. Annotations for metabolic pathways such as
‘sucrose metabolism’, ‘pentose phosphate pathway’ and
‘cholesterol biosynthesis’ were also detected, consistent
with the notion that metabolic pathways may be tar-
geted for therapeutic intervention in HD [3,47]. Addi-
tionally, several modules were annotated for genes of
interest in HD such as druggable genes (as notably
observed in the modules for suppression of 128Q-neu-
ron dysfunction by RNAi; see Additional file 9: Table
S8), htt partners, and genes involved in autophagy, mito-
chondrial function and synaptic activity, which further
illustrated the relevance of our dataset to neuroprotec-
tive target discovery in HD.
Modifiers of 128Q-neuron dysfunction in C. elegans are
dysregulated in the striatum of either CHL2 knock-in mice
or R6/2 transgenic mice
To further assess the relevance of our RNAi data to can-
didate target profiling and discovery in HD, we next
compared our dataset to striatal gene expression data
collected from mouse models of HD. Given that 128Q
nematodes recapitulate progressive neuron dysfunction,
which may occur in HD before cell loss, we compared
our RNAi data to striatal gene expression data collected
from the CHL2(Q150/Q150) knock-in mice, a model
that may recapitulate progressive neuronal injury similar
to that found early in the course of HD [48]. To reach a
more specific level of comparison, we also compared
our data to striatal gene expression data collected from
the R6/2 transgenic mice, a model that exhibits rapid
phenotypic changes as induced by a short N-terminal
fragment of mutant htt [10]. Among the 662 modifiers
of 128Q-neuron dysfunction in C. elegans,2 3 9g e n e s
were conserved in the mouse. Forty-nine genes were
found at the intersection of the C. elegans RNAi data
and gene dysregulation data in HD mice (Figure 4). Six
of these 49 genes including Acy1, Sh3gl3, Snw1, Aars,
Ppp5 and Gpi1 were oppositely dysregulated in the
CHL2 mice compared to R6/2 mice (Figure 4), illustrat-
ing the differences that may exist between these two
models at the molecular level. In contrast, genes that
are involved in a variety of biological processes and that
modulate 128Q-neuron dysfunction when knocked-
down by RNAi were dysregulated in either the CHL2 or
R6/2 mice (Figure 4), illustrating how data comparison
using substractive analysis may be useful for target
prioritisation. Notably, 12 genes that suppress 128Q-
neuron dysfunction when knocked-down by RNAi in C.
elegans were observed to be up-regulated in either the
CHL2 or R6/2 mice, suggesting that inhibiting these
genes might elicit neuroprotection in HD. One of them,
the phenylalanine-4-hydroxylase Pah, appeared to be
particularly interesting since it is a druggable gene that
acts upstream of tyrosine-dopamine biosynthesis and
since increased dopamine levels were previously asso-
ciated with early HD phenotypes such as hyperkinesia
[49].
Discussion
The aim of our study was to collect information on the
genes and pathways that may act as modifiers of the
early stage of mutant htt toxicity in HD such as neuron
dysfunction. To this end, we used an in vivo model to
screen for gene inactivations that modulate the neuronal
dysfunction induced by expanded-polyQ expression in
C. elegans, and we used network-boosted analysis to
enhance the identification of candidate pathways that
may be further evaluated in mammalian systems. We
identified 662 hits from the evaluation of 6034 genes.
Compared to RNAi screens based on biochemical pro-
cesses such as protein aggregation [38-40], the relatively
high number of hits in our study is likely to reflect the
multigenic nature of behavioral phenotypes such as
response to touch rather than changes in polyQ-
expanded htt expression levels. Previously-identified
modulators of neuron dysfunction in expanded-polyQ
nematodes do not change transgene expression levels
[14,18], further suggesting most RNAi effects are not
due to changes in htt expression levels.
In contrast to 128Q-neuron dysfunction, neuronal
dysfunction produced by normal polyQ expression in
our trangenic nematodes is not directly relevant to HD
pathogenesis. Microarray analysis of gene expression in
touch receptor cells isolated by fluorescence-activated
cell sorting indeed indicated that only 18 out of 2000
genes dysregulated by 128Q expression are also dysregu-
lated by 19Q expression (submitted elsewhere), and sev-
eral of the expanded-polyQ cytotoxicity that we
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cytotoxicity [14,18]. Additionally, we observed that
greater than 90% of the modifiers of 128Q-neuron dys-
function showed no effect in 19Q nematodes using a
subset of 243 genes identified by RNAi screening in
128Q nematodes. Collectively, these observations sug-
gest that the mechanisms of neuron dysfunction in 19Q
nematodes [14] are different from those underlying the
strong level of neuron dysfunction in 128Q nematodes.
While specific modifiers of expanded-polyQ cytotoxicity
might constitute preferred HD targets, one cannot
exclude the possibility that non-specific modifiers of
neuron dysfunction in polyQ nematodes may belong to
the core machinery for neuron differentiation and survi-
val, thus being of potential interest, at least from a
screening perspective. This was for example illustrated
by two N-acetylgalactosaminyltransferases (gly-9 and
gly-3), a family of enzymes involved in neuron differen-
tiation and survival [50].
A major feature of network-boosted analysis is to
reduce data complexicity by highlighting individual
pathways and possibly inter-connected pathways that
are embedded into modules seeded with gene activity.
In this respect, the network-boosted data analysis of our
RNAi dataset was more instructive compared to the sole
use of GO annotations or gene set enrichment analysis.
While a role for a variety of pathways was suggested by
gene set enrichment analysis, network-boosted analysis
indeed emphasized a role for these pathways in a more
comprehensive fashion, providing new insights of how
Figure 4 Overlap between 239 conserved modifiers of 128Q-neuron dysfunction in C-elegans and genes dysregulated in the striatum
of either CHL2 knock-in mice or R6/2 transgenic mice.( A) Overlap between dysregulated genes in the mouse striatum and suppressors of
128Q-neuron dysfunction that have mouse orthologs. Numbers of genes are indicated. The lists of genes at the intersection of the nematode
and mouse datasets are indicated below the graphs. (B) Overlap between dysregulated genes in the mouse striatum and enhancers of 128Q-
neuron dysfunction that have mouse orthologs. The numbers of genes is indicated. The lists of genes at the intersection of the nematode and
mouse datasets are indicated below the graphs. Some genes are oppositely dysregulated in the CHL2 mice compared to R6/2 mice (yellow
tags). In all panels, red circles indicate C. elegans genes that modify 128Q-neuron toxicity. *Druggable genes.
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within modules. Furthermore, network-boosted analysis
identified pathways not detected by gene set enrichment
analysis. As indicated by the pathways embedded in the
modules resulting from network-boosted analysis (see
the on-line database at http://www.broca.inserm.fr/
EHDN2/RNAiscreen), a role for neurodegenerative dis-
ease pathways and neurodevelopmental/cell survival
pathways in the modulation of expanded-polyQ cyto-
toxicity was emphasized, which may provide guidance to
the selection of candidate targets for neuroprotection in
HD. The annotation of the modules resulting from net-
work-boosted analysis identified clusters enriched in
genes of interest such as druggable genes, htt partners
and genes involved in autophagy, mitochondrial function
and synaptic activity (all gene classes which can be quer-
ied using the on-line database), providing additional gui-
dance to neuroprotective target discovery in HD. Here,
it is important to note that the hypothesis underlying
network-based approaches is that highly-interconnected
genes might show similar biological activities. In this
respect, the network-boosted analysis of our data is pre-
dictive of the genes that might decrease or increase
128Q-neuron dysfunction when knocked-down by
RNAi, even though they showed no effect or borderline
effects in the RNAi screen. While this may increase the
number of candidate targets to be considered for neuro-
protective intervention, it decreases the risk for noise
associated with RNAi screens and favors the inclusion
of potentially-interesting information for multi-model
target discovery.
Multi-model target discovery is strongly expected to
enhance the drug discovery process for neuroprotection
in HD. A standard method for the validation of modi-
fiers of neuronal dysfunction as instructed by simple
models of HD pathogenesis relies on target validation in
the mouse. Because it is not yet feasible to test in the
mouse all genes supported as modifiers of neuronal
decline in simple models, the outcome of our functional
screen and other screens will be analyzed using data
integration procedures in which the selection of the best
targets for validation will rely on target expression levels
a n da c t i v i t yi nm u l t i p l em o d e l so fH D .O n eo ft h e
objectives of data integration is to assess the relevance
of simple-model data to mouse models, and more lar-
gely to human neurodegenerative disease. In this
respect, it is notable that several modifiers of 128Q-neu-
ron dysfunction found in our screen were previously
associated with the pathogenesis of neurodegenerative
diseases such as HD or AD, suggesting that our C. ele-
gans dataset is relevant to HD pathogenesis in higher
order models of the disease. This is for example the
case for four genes retained by network-boosted analysis
including (i) dnj-1/DNAJ, a gene that encodes a DNAJ
chaperone [51], aggravates neuron dysfunction when
knocked-down by RNAi and is down-regulated in the
CHL2 mice, (ii) sel-8,aC. elegans gene that encodes a
nuclear protein required for lin-12/NOTCH signaling,
which may have neuron survival activities [52], and that
aggravates 128Q-neuron dysfunction when knocked-
down by RNAi, (iii) jnk-1/JNK, a gene that promote HD
pathology in a rat model of the disease [53] and sup-
presses 128Q-neuron dysfunction when knocked-down
by RNAi, and (iv) pnk-1/PanK4, a gene that encodes a
panthotenate kinase and suppresses 128Q-neuron dys-
function when knocked-down by RNAi, which is consis-
tent with the pathological role of panthotenate kinases
in neurodegeneration [45]. Additionally, the comparison
of our data to gene dysregulation in the striatum of
CHL2 knock-in mice versus that of R6/2 transgenic
mice further indicated that our dataset contains infor-
mation relevant to HD target selection as illustrated by
the proposed inhibition of phenylalanine-4-hydroxylase
as a candidate strategy to reduce early HD phenotypes
that may be associated to a transient excess of dopamine
[49].
Conclusions
In conclusion, our results provide new insights into the
genes and pathways that might regulate the dysfunction
and death of neurons expressing mutant polyQs,
emphasizing a role for specific metabolic, developmental
and pro-survival pathways. Several models of HD are
being used to screen for modifiers of mutant polyQ
toxicity and for genes dysregulated by mutant htt. In
this context, the use of cross-species data integration for
the analysis of our RNAi dataset and other datasets is
anticipated to boost the prediction and prioritisation of
neuroprotective targets in HD, and this will be investi-
gated in additional studies.
Additional material
Additional file 1: Figure S1. Distribution of S scores for the primary
screen in 128Q;rrf-3 nematodes. The graph shows the S scores for 4017
RNAi clones that did not elicit lethality or developmental abnormalities.
The S score was calculated as [(Percent response - mean baseline)/mean
baseline]. The maximally-achievable score is 4.55 (100% response to
touch) and the smallest score is -1 (complete loss of touch response).
The blue line indicate the mean baseline (S = 0). Dooted blue lines show
the mean baseline ± SD*2.6. Clones with S scores falling outside the
mean baseline ± SD*2.6 interval were retained for the secondary screen.
Additional file 2: Table S1. List of the 2211 genes that caused lethality
and developmental abnormalities when knocked-down by RNAi.
Additional file 3: Table S2. List of the 3823 genes that either showed
no effect or modified 128Q-neuron dysfunction when knocked-down by
RNAi in the primary screen.
Additional file 4: Table S3. List of the 662 genes that modified 128Q-
neuron dysfunction when knocked-down by RNAi in the secondary
screen.
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Page 12 of 14Additional file 5: Table S4. List of the 15 genes that modified 19Q-
neuron dysfunction when knocked-down by RNAi.
Additional file 6: Table S5. List of the 15 genes that modified 128Q-
neuron dysfunction in the secondary screen and were previously
reported to modify polyQ aggregation when knocked-down by RNAi.
Additional file 7: Table S6. Gene Ontology classification of genes that
suppressed 128Q-neuron dysfunction when knocked-down by RNAi.
Additional file 8: Table S7. Gene Ontology classification of genes that
aggravated 128Q-neuron dysfunction when knocked-down by RNAi.
Additional file 9: Table S8. Modules (n = 137) generated by network-
boosted analysis for suppression of 128Q-neuron dysfunction by RNAi.
Additional file 10: Table S9. Modules (n = 105) generated by network-
boosted analysis for aggravation of 128Q-neuron dysfunction by RNAi.
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